New Treatment for Patients with Peripheral T-cell Non-Hodgkin Lymphoma

• As a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Fox Chase Cancer Center offers our patients the most advanced treatment options through clinical trials, many of which are not readily available elsewhere. Our nationally ranked doctors specialize in the development of these studies — specifically phase 1 and 2 trials.

  

  In this issue we highlight a phase 2 clinical trial for Peripheral T-cell Non-Hodgkin lymphoma that is led by Stefan K. Barta, MD, a medical oncologist at Fox Chase who specializes in Hematologic cancers.

  
  The purpose of the clinical trial is to find out if pembrolizumab can improve your disease and increase progression free survival; to determine the tolerability and safety of pembrolizumab; and if there are markers or special characteristics in the cancer tissue and blood that go along with response to treatment and survival.

  About 25 male and female patients over the age of 18 years with relapsed or refractory Peripheral T-cell Non-Hodgkin lymphoma will participate in this study. Patients must have T-cell lymphoma that has progressed after systemic therapy, show measureable disease on a PET/CT scan, and have no active autoimmune disease. Patients with a history of HIV, Hepatitis B, or Hepatitis C may not participate.

  Learn more about clinical trials offered at Fox Chase.